IXHLHealthcare · Drug Manufacturers - Specialty & GenericIXHL Stock Forecast: Incannex Healthcare, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Incannex Healthcare, Inc. hold a median 12-month price target of $18 — +508.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
IXHL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Incannex Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (84): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Incannex Healthcare, Inc. — and when they’d sell — is the membership.
IXHL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IXHL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +508.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 June 2026 | Alliance Global Partners | Initiates | Buy | $18 |
| 8 June 2026 | Alliance Global Partners | Initiates | Buy | — |
| 8 Dec 2022 | Mizuho | Maintains | Neutral | — |
| 16 Nov 2022 | Keybanc | Downgrade | Sector Weight | — |
| 3 Nov 2022 | Barclays | Maintains | Overweight | — |
| 3 Nov 2022 | Mizuho | Downgrade | Neutral | — |
| 3 Nov 2022 | Raymond James | Maintains | Outperform | — |
| 3 Nov 2022 | RBC Capital | Maintains | Outperform | — |
| 3 Nov 2022 | Truist Securities | Downgrade | Hold | — |
| 24 Oct 2022 | Keybanc | Maintains | Overweight | — |
| 24 Oct 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 24 Oct 2022 | RBC Capital | Maintains | Outperform | — |
| 24 Oct 2022 | Truist Securities | Maintains | Buy | — |
| 21 Oct 2022 | Needham | Downgrade | Hold | — |
| 17 Oct 2022 | Mizuho | Maintains | Buy | — |
| 11 Oct 2022 | Canaccord Genuity | Initiates | Buy | — |
| 23 Sept 2022 | BTIG | Initiates | Neutral | — |
| 4 Aug 2022 | Mizuho | Maintains | Buy | — |
| 4 Aug 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 4 Aug 2022 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IXHL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Incannex Healthcare, Inc. (IXHL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- —
- Price / book
- 0.5×
- EV / EBITDA
- 1.6×
Cheaper than 76% of US stocks
Cheaper than 83% of US stocks
Cheaper than 57% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −117.2%
- Return on assets
- −32.2%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IXHL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IXHL appears on the weeks it earns a place.
Frequently asked questions about IXHL stock
What is the IXHL stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Incannex Healthcare, Inc. have a median 12-month price target of $18, with estimates ranging from $18 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IXHL stock a buy right now?
Of the 1 analysts covering Incannex Healthcare, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Incannex Healthcare, Inc. 22 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IXHL?
As at 1 Aug 2026, Incannex Healthcare, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).
Will IXHL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +508.2% from the last close, and Ticker Nerd's factor model ranks Incannex Healthcare, Inc. 22 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IXHL stock forecast for 2030?
No analyst covering Incannex Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IXHL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $18 over the next 12 months.
How has IXHL stock performed over the past year?
Incannex Healthcare, Inc. returned -74.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Incannex Healthcare, Inc. do?
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and advancing novel oral fixed-dose combination therapies for chronic conditions.
About Incannex Healthcare, Inc.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and advancing novel oral fixed-dose combination therapies for chronic conditions. Its lead candidate, IHL-42X, combines dronabinol and acetazolamide to target obstructive sleep apnea through synergistic action on intermittent hypoxia and hypercapnia. PSX-001, an oral synthetic psilocybin formulation administered with psychotherapy, addresses generalized anxiety disorder. Additionally, IHL-675A pairs synthetic cannabidiol with hydroxychloroquine sulfate to combat inflammation in rheumatoid arthritis, lung conditions like chronic obstructive pulmonary disease and asthma, and inflammatory bowel diseases including colitis and Crohn’s. Incannex Healthcare Inc. emphasizes reducing individual drug dosages in combinations to minimize side effects while enhancing efficacy. Founded in 2001 and headquartered in Sydney, Australia, the company operates in the specialty drug manufacturing sector, prioritizing psychedelic and cannabinoid-based innovations for unmet medical needs in respiratory, neurological, and inflammatory disorders.
CEO Mr. Joel Bradley Latham · 12 employees · Australia · https://www.incannex.com